Synopsis Teprotumumab therapy provided clinical benefit in patients with active, moderate-to-severe thyroid-associated ophthalmopathy. The present study aims to determine the efficacy and safety of teprotumumab in the patients with Thyroid-Associated Ophthalmopathy. This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “ Teprotumumab for Thyroid-Associated Ophthalmopathy” . Authors: Terry J. Smith, George J. Kahaly et.
al. Key Takeaways: Teprotumumab therapy is effective in patients with active, moderate-to-severe thyroid-associated ophthalmopathy. Objective: To determine the efficacy and safety of teprotumumab in the patients with Thyroid-Associated Ophthalmopathy. Study Type: multicenter, double-masked, randomized, placebo-controlled trial Participants: 87 What was the need for this study? The effective and safe use of Teprotumumab in…
